Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy
- Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing
- A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy®
PLAINSBORO, N.J., June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers, a global leader in science-backed weight management, beginning July 1, 2025. WeightWatchers will work with CenterWell Pharmacy as the dispensing pharmacy managing prescription fulfilment and delivery for NovoCare® Pharmacy. By extending access to Wegovy® through their integrated support system, WeightWatchers aims to provide patients with a more streamlined experience, along with convenient access to FDA-approved medication with the lifestyle support shown to improve outcomes.